Also, we have initiated a new trial for metastatic melanoma patients using young-TIL ACT in combination with intermediate doses of IL-2 (ClinicalTrials.gov ID: NCT00937625) with the purpose of defining the most optimal dose of IL-2 for the use in a larger randomized clinical trial. Here, IL2 is linked to metastatic melanoma.